β-Blockers are competitive antagonists at β-adrenergic receptors (β-AR) and are a life-saving form of treatment in different cardiovascular diseases (CVD). Despite current guidelines supporting the use of selective β1-blockers in patients with CVD and especially in heart failure (HF), they are still largely underused, mostly as a consequence of the presence of chronic obstructive pulmonary disease (COPD). In primary care, prevalence of COPD in patients with HF is approximately 25%, and it will rise in the next years. In the general population, only 20% of COPD patients with HF are treated with β-blockers. β-Blockers may result in pulmonary adverse effects that are relevant to COPD patients. Bronchoconstriction may be the consequence of: absence of cardioselectivity; loss of cardioselectivity at high doses, and unopposed stimulation of cholinergic muscarinic M2 receptors. The concern of inducing bronchospasm is the more likely explanation of a poor prescription of β-blockers in patients with CVD also suffering from COPD. However, under carefully controlled conditions, which include close monitoring of lung function and appropriate selection of the drug and titration of the dose on a case-by-case basis, selective β1-blockers can be safely administered to most patients with COPD. Pneumologists and cardiologists should develop a detailed and standardized protocol to guide the use of selective β1-blockers in everyday practice, which could significantly reduce the physicians’ mistrust of β-blockers in COPD patients.

1.
Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
2.
Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112–119.
3.
Kuller LH, Ockene JK, Townsend M, Browner W, Meilahn E, Wentworth DN: The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis 1989;140:S76–S81.
4.
Sin DD, Anthonisen RR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245–1257.
5.
McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411–415.
6.
Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring EJ, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63–70.
7.
Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G: The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007;9:942–948.
8.
Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW: Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706–711.
9.
Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM: Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J 2002;143:412–417.
10.
Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ: Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.
11.
Hawkins NM, Jhund PS, Simpson CR, Petrie MC, MacDonald MR, Dunn FG, MacIntyre K, McMurray JJV: Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010;12:1–8.
12.
Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–2442.
13.
Boudestein LCM, Rutten FH, Cramer MJ, Lammers JW, Hoes AW: The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11:1182–1188.
14.
Huiart L, Ernst P, Suissa S: Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640–2646.
15.
Lainscak M, Hodoscek LM, Düngen HD, Rauchhaus M, Doehner W, Anker SD, von Haehling S: The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009;121:309–313.
16.
Sirak TE, Jelic S, Le Jemtel TH: Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004;44:497–502.
17.
Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardacchia B, Pistelli R: Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794–2800.
18.
Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E: Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005;98:493–497.
19.
Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Wolf SH: Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003;123:222–243.
20.
Floras JS: Sympathetic nervous system activation in human heart failure. Clinical implications of an updated model. J Am Coll Cardiol 2009;54:375–385.
21.
Carstairs JR, Nimmo AJ, Barnes PJ: Autoradiographic visualization of beta adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985;132:541–547.
22.
van Koppen CJ, Hermanussen MW, Verrijp KN, Rodrigues de Miranda JF, Beld AJ, Lammers JW, van Ginneken CA: β-Adrenoceptors in human tracheal smooth muscle: characteristics of binding and relaxation. Life Sci 1987;40:2561–2570.
23.
Abraham G, Kottkea C, Dheinb S, Ungemacha FR: Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract. Biochem Pharmacol 2003;66:1067–1081.
24.
Brodde OE: β1- and β2-adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. Pharmacol Rev 1991;43:203–242.
25.
Matera MG, Martuscelli E, Cazzola M: Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther 2010;23:1–8.
26.
Baker JG: The selectivity of b-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 2005;144:317–322.
27.
Molenaar P, Chen L, Semmler ABT, Parsonage WA, Kaumann AJ: Human heart β-adrenoceptors: β1-adrenoceptor diversification through affinity states and poly- morphism. Clin Exp Pharmacol Physiol 2007;34:1020–1028.
28.
Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC, National Heart Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363–2372.
29.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A: 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–1187.
30.
Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB: Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301–305.
31.
Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L: Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003;145:438–444.
32.
Bradford WD, Chen J, Krumholz HM: Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics 1999;15:257–268.
33.
Cleland JG, Cohen-Solal A, Aguila JC, Dietz R, Follath F, Freemantle N, Gavazzi A, van Gilst GW, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J, IMPROVEMENT of Heart Failure Programme Committees and Investigators: Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002;360:1631–1639.
34.
Erdmann E: Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J 2009;11(suppl A):A21–A25.
35.
Frishman WH: β-Adrenergic blockers: a 50-year historical perspective. Am J Ther 2008;15:565–576.
36.
Reiter MJ: Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 2004;47:11–33.
37.
Ashrfian H, Violaris AG: Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir 2005;14:236–241.
38.
Coats AJ: Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging 2006;23:93–99.
39.
Antonelli Incalzi R, Pedone C: Respiratory effects of β-adrenergic receptor blockers. Curr Med Chem 2007;14:1121–1128.
40.
Andrus MR, Loyed JV: Use of β-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging 2008;25:131–144.
41.
Novakova M, Myslivecek J: Identification of all α1-adrenoceptor subtypes in rat lung. Gen Physiol Biophys 2005;25:349–353.
42.
Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, Giles H, Shardonofsky FR, Bond RA: Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 2004;101:4948–4953.
43.
Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ: 2009 ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol 2009;54:2102–2128.
44.
Selzman CH, Miller SA, Zimmerman MA, Harken AH: The case for beta-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality. Arch Surg 2001;136:286–290.
45.
Van Gestel Y, Hocks SE, Sin DD, Schouten O, Witteven HJ, Simsek C, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D: Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008;178:695–700.
46.
Rajeev S, Wong DT: Effect of beta-blockers on perioperative myocardial ischemia in patients undergoing noncardiac surgery. Curr Drug Targets 2009;10:833–841.
47.
Schouten O, Shaw LJ, Boersma E, Bax JJ, Kertai MD, Feringa HH, Biagini E, Kok NF, Urk H, Elhendy A, Poldermans D: A meta-analysis of safety and effectiveness of perioperative beta-blocker use for the prevention of cardiac events in different types of noncardiac surgery. Coron Artery Dis 2006;17:173–179.
48.
McGory ML, Maggard MA, Ko CY: A meta-analysis of perioperative beta blockade: what is the actual risk reduction? Surgery 2005;138:171–179.
49.
Domanski D, Schwarz ER: Is the perioperative use of β-blockers still recommended? A critical review of recent controversies. J Cardiovasc Pharmacol Ther 2009;14:258–268.
50.
Talati R, Reinhart KM, White CM, Pungh OJ, Sedrakyan A, Kluger J, Coleman CJ: Outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery: a meta-analysis. Ann Pharmacother 2009;43:1181–1188.
51.
Freemantle N, Cleland J, Young P, Mason J, Harrison J: β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730–1737.
52.
Gheorghiade M, Goldstein S: Beta blockers in the post myocardial infarction patient. Circulation 2002;106:394–398.
53.
Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489–497.
54.
Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM: Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950–1956.
55.
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJV, Maggioni AP: Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11:292–298.
56.
Andrus MR, Holloway KP, Clark DB: Use of beta-blockers in patients with COPD. Ann Pharmacother 2004;38:142–145.
57.
Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, Fihn SD: Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004;117:925–931.
58.
Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink L: Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;1:CD002003.
59.
Hogg K, McMurray J: The treatment of heart failure with preserved ejection fraction (‘diastolic heart failure’). Heart Fail Rev 2006;11:141–146.
60.
Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, Agostoni PG: Lung function and exercise gas exchange in chronic heart failure. Circulation 1997;96:2221–2227.
61.
Kotlyar E, Keogh AM, MacDonald PS, Arnold RH, McCaffrey DJ, Glanville AR: Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002;21:1290–1295.
62.
Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C: Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J 2006;27:2538–2543.
63.
Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJV: Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized con- trolled trial. Eur J Heart Fail 2009;11:684–690.
64.
Ind PW: Catecholamines; in Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ (eds): Asthma. Philadelphia, Lippincott-Raven, 1997, pp 977–1008.
65.
Cazzola M, Noschese P, Matera MG: The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002;121:230–241.
66.
Boushey HA, Holtzman MJ, Sheller JR, Nadel JA: Bronchial hyperreactivity. Am Rev Respir Dis 1980;121:389–413.
67.
Chetta A, Foresi A, Garavaldi G, Corbo GM, Olivieri D: Evaluation of bronchial responsiveness by pharmacological challenges in asthma: inhaled propranolol in comparison with histamine and methacholine. Respiration 1988;54(suppl 1):184–189.
68.
Gross NJ, Skorodin MS: Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421–425.
69.
Rebuck AS, Chapman KR, Abboud R, Pare PD, Kreisman H, Wolkove N, Vickerson F: Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987;82:59–64.
70.
On LS, Boonyongsunchai P, Webb S, Davies L, Davies L, Calverley PM, Costello RW: Function of pulmonary neuronal M2 muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1320–1325.
71.
Godfrey S, Konig P: Inhibition of exercise-induced asthma by different pharmacological pathways. Thorax 1976;31:137–143.
72.
Ney UM: Propranolol-induced airway hyperreactivity in guinea-pigs. Br J Pharmacol 1983;79:1003–1010.
73.
Van Mieghem W, Stevens E, Billiet L: Phentolamine therapy in severe chronic asthmatiform bronchitis. Respiration 1981;42:184–187.
74.
Black JL, Temple DM, Anderson SD: Long-term trial of an alpha-1 adrenoceptor blocking drug (Indoramin) in asthma: a preliminary report. Scand J Respir Dis 1978;59:307–312.
75.
Mathe AA, Astrom A, Persson NA: Some bronchoconstricting and bronchodilating responses of human isolated bronchi: evidence for the existence of alpha-adrenoceptors. J Pharm Pharmacol 1971;23:905–910.
76.
van Zwieten PA: Pharmacodynamic profile of carvedilol. Cardiology 1993;82(suppl): 19–23.
77.
van der Woude HJ, Zaagsma J, Postma DS, Aalbers R, van Hulst M: Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest 2005;127:818–824.
78.
Salpeter S, Omiston T, Salpeter E: Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD003566.
79.
Ind PW, Dixon CM, Fuller RW, Barnes PJ: Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989;139:1390–1394.
80.
George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT: Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 1983;83:457–460.
81.
Münzel T, Gori T: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491–1499.
82.
Dal Negro R: Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis 2009;3:329–334.
83.
Le Jemtel TH, Padeletti M, Jelic S: Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49:171–180.
84.
Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O’Connor BJ, Page C, Bond RA: The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008;21:134–141.
85.
Mutlu GM, Koch WJ, Factor P: Alveolar epithelial β2-adrenergic receptors. Their role in regulation of alveolar active sodium transport. Am J Respir Crit Care Med 2004;170:1270–1275.
86.
Puri S, Dutka DP, Baker BL, Hughes JMB, Cleland JGF: Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation 1999;99:1190–1196.
87.
Crone C, Saumon G, Basset G: News from the alveoli. News Physiol 1990;5:50–53.
88.
Brooks TW, Creekmore FM, Young DC, Asche CV, Samuelson WM: Rates of hospitalizations and emergency department vis- its in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007;27:684–690.
89.
Ng TM, Munger MA, Lombardi WL, Doing TH, Ryujin DT, Young DC, Lugo RA: Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol 2002;40:140–145.
90.
Azuma J, Nonen S: Chronic heart failure: β-blockers and pharmacogenetics. Eur J Clin Pharmacol 2009;65:3–17.
91.
Camsari A, Arikan S, Avan C, Kaya D, Pekdemir H, Ciçek D, Kiykim A, Sezer K, Akkuş N, Alkan M, Aydoğdu S: Metoprolol, a β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003;18:188–192.
92.
Agostoni P, Contini M, Apostolo A, Sciomer S, Palermo P, Fiorentini P: Lung function with carvedilol and bisoprolol in chronic heart failure: is β-selectivity relevant? Eur J Heart Fail 2007;9:827–833.
93.
Agostoni P, Palermo P, Contini M: Respiratory effects of beta-blocker therapy in heart failure. Cardiovasc Drugs Ther 2009;23:377–384.
94.
Popio KA, Jackson DH Jr, Utell MJ, Swinburne AJ, Hyde RW: Inhalation challenge with carbachol and isoproterenol to predict bronchospastic response to propranolol in COPD. Chest 1983;83:175–179.
95.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–1554.
96.
Woolcock AJ, Anderson SD, Peat JK, Du Toit JI, Zhang YG, Smith CM, Salome CM: Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438–1443.
97.
Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O’Byrne PM, Anderson SD, Juniper EF, Malo JL: Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:53–83.
98.
Shah SM, Carey IM, DeWilde S, Richards N, Cook DG: Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract 2008;58:862–869.
99.
Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM: Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006;51:1120–1124.
100.
Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-474.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.